Physician profile
Nick Stull
NPI 1053935890
$2,623.01
in general payments reported to CMS, 2019-2025
18 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $391 · 2022: $857 · 2023: $781 · 2024: $340 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $511.96 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $373.43 | 2021-2025 | |
| Alkermes, INC. | $280.24 | 2021-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $227.07 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $224.51 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.16 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $164.11 | 2022-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $113.61 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $105.53 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $103.90 | 2022-2024 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $77.42 | 2022-2024 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $56.03 | 2021-2025 | Trintellix |
| Neuronetics, INC. | $53.69 | 2022-2023 | Neurostar Tms Therapy System |
| Biogen, INC. | $36.67 | 2024 | |
| Idorsia Pharmaceuticals US INC | $36.60 | 2022-2023 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $32.52 | 2022 | |
| Almatica Pharma LLC | $21.51 | 2024 | Loreev Xr |
| Tris Pharma INC | $18.05 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Stull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.